Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Recro Pharma, Inc. (REPH): Here are Midwood Capital Management’s Thoughts On The Pharmaceutical Company

Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter. If you are interested you can find a copy of the letter here.  The fund also disclosed the quarterly return of 10.6%, and an annualized return since inception of 9.5%.

“Recro Pharma, Inc. (REPH; $8.36; $184million market cap): We highlighted REPH in our Fourth Quarter 2018 Letter to Investors–when the stock was at $7.91 –believing that one key catalyst would be FDA approval of REPH’s new drug application for Intravenous Meloxicam(IVM), a non-opioid drug for moderate to severe acute pain. REPH had a PDUFA date for completion of the FDA’s review by March 26, 2019. Our analysis indicated that the probability of IVM’s approval was high. Unfortunately, however, REPH received a second Complete Response Letter on March 22 indicating that the FDA would not approve its NDA in its present form. The stock, which had crept up to $9.72 prior to the announcement, fell as much as 43%. However, management has already taken actions that reinforce our belief –and the market’s –that the company will maximize value for shareholders by curtailing its acute care drug development program and monetizing its valuable CDMO business. These positive developments have caused the stock to recover from the mid-$5s. REPH dragged on the Fund’s performance by 74 bps in the first quarter”

Recro Pharma, Inc. (REPH): Here are Midwood Capital Management's Thoughts On The Pharmaceutical Company

Copyright: nexusplexus / 123RF Stock Photo

Recro Pharma, Inc. is a specialty pharmaceutical company with a market cap of $193.74 million. Year-to-date, the company’s stock gained 18.89%, and on May 7th it had a closing price of $8.81.

Heading into the first quarter of 2019, a total of 11 of the hedge funds tracked by Insider Monkey were long this stock, a change of -21% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in REPH over the last 14 quarters. With hedgies’ capital changing hands, there exists an “upper tier” of notable hedge fund managers who were adding to their holdings significantly (or already accumulated large positions).

Among these funds, Broadfin Capital held the most valuable stake in Recro Pharma Inc (NASDAQ:REPH), which was worth $14.5 million at the end of the third quarter. On the second spot was Newtyn Management which amassed $11.4 million worth of shares. Moreover, Alyeska Investment Group, Engine Capital, and Renaissance Technologies were also bullish on Recro Pharma Inc (NASDAQ:REPH), allocating a large percentage of their portfolios to this stock.

REPH

Dislcosure: None.
This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...